Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A stable, aqueous formulation comprising natalizumab, a phosphate buffer, a polysorbate, and sodium chloride.

2. (Original) The formulation of claim 1, wherein the polysorbate is polysorbate 80.

3. (Original) The formulation of claim 2, wherein the polysorbate 80 is present in an amount of about 0.001% to about 2.0% (w/v).

4. (Original) The formulation of claim 3, wherein the polysorbate 80 is present in the amount of about 0.02% (w/v).

5. (Previously Presented) The formulation of claim 1, wherein natalizumab is present in the amount of about 0.1 mg/mL to about 200 mg/mL.

6. (Canceled)

7. (Previously Presented) The formulation of claim 5, wherein natalizumab is present in the amount of about 5 mg/mL.

8. (Previously Presented) The formulation of claim 5, wherein natalizumab is present in the amount of about 20 mg/mL.

9. (Original) The formulation of claim 1, wherein the formulation has a pH of about 3.0 to about 7.0.

10. (Original) The formulation of claim 9, wherein the pH is about 5.5 to about 6.5.

11. (Previously Presented) The formulation of claim 10, wherein the pH is about 6.0 +/- 0.5.

12. (Previously Presented) The formulation of claim 1, wherein the formulation is in a fixed volume and natalizumab is present in the amount of about 50 mg/mL.

13.-14. (Canceled)

15. (Previously Presented) The formulation of claim 1, wherein the phosphate buffer is at pH 6.0 +/- 0.5, the polysorbate is polysorbate 80 and is present in an amount of about 0.02% (w/v), and wherein the formulation is stable at a temperature of about 2 °C to about 8 °C for at least 6 months.

16. (Original) The formulation of claim 15, wherein natalizumab is present in an amount of about 20 mg/mL to about 150 mg/mL.

17. (Original) The formulation of claim 1, wherein the formulation is isotonic.

18.-22. (Canceled)

23. (Previously Presented) The formulation of claim 1, wherein natalizumab is present in the amount of about 15 mg/mL to about 50 mg/mL.

24.-28. (Canceled)

29. (Previously Presented) A composition comprising a sodium phosphate, a polysorbate, natalizumab, and sodium chloride with a pH of 6.0 +1-0.5, wherein the composition is stable when stored at about 2 °C to about 8° C for greater than 6 months.

30. (Original) The composition of claim 29, wherein the polysorbate is polysorbate 80 and is present in an amount of about 0.001% to about 2.0% (w/v).

31. (Previously Presented) The composition of claim 29, wherein natalizumab is present in an amount of about 0.01 mg/mL to about 200 mg/mL.

32. (Previously Presented) The composition of claim 29, wherein the polysorbate is polysorbate 80 and is present in the amount of about 0.02% (w/v), the sodium chloride is present in the amount of 150 mM, the phosphate buffer is present in the amount of 10 mM, and natalizumab is present in the amount of 1.7 mg/mL, 5 mg/mL , 20 mg/mL or 50 mg/mL.

33.-40. (Canceled)

41. (Original) An article of manufacture comprising a container holding the stable formulation of claim 1.

42. (Canceled)

43. (Previously Presented) A stable, aqueous formulation comprising:
20 mg of natalizumab;

140 mM sodium chloride;

0.02% polysorbate 80 (w/v); and

10 mM sodium phosphate.

44. (Previously Presented) The formulation of claim 43, wherein the formulation is stable at about 2 °C to about 8 °C for six months.

45. (Previously Presented) The formulation of claim 1, wherein the natalizumab is present in the amount of about 0.1 mg/mL to about 150 mg/mL.